BuqitongluO Granule for Qi Deficiency and Blood Stasis Syndrome

Overview

The main purpose of this trial is to evaluate the efficacy and safety of Buqitongluo Granule in treating qi deficiency and blood stasis syndrome, and explore the effect of the improvement of qi deficiency and blood stasis syndrome on the prognosis of diseases.

Full Title of Study: “Buqitongluo Granule for Qi Deficiency and Blood Stasis Syndrome: A Multicenter, Randomized, Double-blind, Placebo-Controlled Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: December 2022

Detailed Description

The BOSS study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The primary hypothesis of this trial is that Buqitongluo Granule will improve the syndrome score of Qi Deficiency and Blood Stasis in convalescence of ischemic stroke, stable angina pectoris of coronary artery disease and diabetic peripheral neuropathy with qi deficiency and blood stasis syndrome. Buqitongluo Granule will be compared to placebo, combined with guidelines-based standard care in patients. During the trial, it is forbidden to use acupuncture, Traditional Chinese Medicine decoction (compound granule), Traditional Chinese Medicine injection, Chinese patent medicine (including external use), external washing of Traditional Chinese Medicine and health product (composition or efficacy similar to the study drug).

Interventions

  • Drug: Buqitongluo Granule
    • Buqitongluo Granules were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.
  • Drug: Buqitongluo Granule Placebo
    • Buqitongluo Granule placeboes were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.
  • Other: Standard care
    • Guidelines-based standard care for convalescence of ischemic stroke, stable angina pectoris of coronary artery disease or diabetic peripheral neuropathy.

Arms, Groups and Cohorts

  • Experimental: Buqitongluo Granule
    • Subjects will receive orally administered Buqitongluo Granules, combined with guidelines-based standard care.
  • Placebo Comparator: Placebo
    • Subjects will receive orally administered Buqitongluo Granule placeboes, combined with guidelines-based standard care.

Clinical Trial Outcome Measures

Primary Measures

  • Change in the syndrome score of Qi Deficiency and Blood Stasis
    • Time Frame: Baseline, at day 14, day 28, day 42 during treatment, and at day 14 after treatment
    • The dynamic evaluation will be defined by Evaluation Scale of Qi Deficiency and Blood Stasis Syndrome. The Evaluation Scale of Qi Deficiency and Blood Stasis Syndrome score ranges from 0 (best score) to 51 (worst score).

Secondary Measures

  • Neurological impairment will be evaluated by National Institute of Health Stroke Scale (NIHSS) for convalescence of ischemic stroke
    • Time Frame: Baseline, at day 14, day 28, day 42 during treatment
    • The NIHSS score ranges from 0 (best score) to 42 (worst score).
  • Self-rating symptoms will be evaluated by Visual Analog Scale (VAS) for convalescence of ischemic stroke
    • Time Frame: Baseline, at day 14, day 28, day 42 during treatment, and at day 14 after treatment
    • Including limb numbness, swelling of hands or feet, spontaneous sweating (hemilateral sweating). Participants rated their symptoms on the 100 millimeter (mm) Visual Analog Scale (VAS) ranging from 0 mm (no symptom) to 100 mm (worst symptom).
  • Continuous changes of Modified Rankin Scale for convalescence of ischemic stroke
    • Time Frame: Baseline, at day 42 during treatment, and at 90 days after onset
    • The Modified Rankin Scale score ranges from 0 (best score) to 6 (worst score).
  • Activities of daily living will be measured by Barthel Index (BI) score for convalescence of ischemic stroke
    • Time Frame: Baseline, at day 42 during treatment, and at 90 days after onset
    • The Barthel Index score ranges from 0 (worst score) to 100 (best score).
  • Quality of life will be measured by Short Form 36 (SF-36) Quality of Life Scale for convalescence of ischemic stroke
    • Time Frame: Baseline, at day 42 during treatment, and at 90 days after onset
    • The SF-36 quality of life scale is used to monitor change in subject reported functionality, well-being, and overall health status. The score of each part ranges from 0 (worst score) to 100 (best score).
  • Change of the Seattle Angina Questionnaire (SAQ) Score for stable angina pectoris of coronary artery disease
    • Time Frame: Baseline, at day 28 during treatment, at day 14 after treatment, and at 90 days after recruitment
    • The maximum score is 100, and the higher the score, the better the quality of life and the state of body function of patient.
  • Self-rating symptoms will be evaluated by Visual Analog Scale (VAS) for stable angina pectoris of coronary artery disease
    • Time Frame: Baseline, at day 14, day 28, day 42 during treatment, and at day 14 after treatment
    • Including chest tightness, chest pain, palpitation, fatigue, spontaneous sweating. Participants rated their symptoms on the 100 millimeter (mm) Visual Analog Scale (VAS) ranging from 0 mm (no symptom) to 100 mm (worst symptom).
  • Change of the Clinical Scoring System of Toronto (TCSS) for diabetic peripheral neuropathy
    • Time Frame: Baseline, at day 14, day 28, day 42 during treatment, at day 14 after treatment, and at 90 days after recruitment
    • TCSS includes a score of neural symptoms, nerve reflex scores and sensory examination. The TCSS score ranges from 0 (best score) to 19 (worst score).
  • Self-rating symptoms will be evaluated by Visual Analog Scale (VAS) for diabetic peripheral neuropathy
    • Time Frame: Baseline, at day 14, day 28, day 42 during treatment, and at day 14 after treatment
    • Including local pain, limb numbness, paresthesia (e.g. burning sensation, formication, electrical sensation). Participants rated their symptoms on the 100 millimeter (mm) Visual Analog Scale (VAS) ranging from 0 mm (no symptom) to 100 mm (worst symptom).
  • Quality of life will be measured by Short Form 36 (SF-36) Quality of Life Scale for stable angina pectoris of coronary artery disease and diabetic peripheral neuropathy
    • Time Frame: Baseline, at day 42 during treatment, and at 90 days after recruitment
    • The SF-36 quality of life scale is used to monitor change in subject reported functionality, well-being, and overall health status. The score of each part ranges from 0 (worst score) to 100 (best score).

Participating in This Clinical Trial

Convalescence of ischemic stroke Inclusion Criteria:

  • Diagnosis of qi deficiency and blood stasis syndrome – Diagnosis of ischemic stroke – Age ≥ 35 and ≤ 80 years – The interval from the onset to recruitment was 14-30 days – NIHSS score ≥ 4 and ≤ 22 – Patient or legally authorized representative has signed informed consent. Exclusion Criteria:

  • Confirmed secondary stroke caused by tumor, brain trauma, or hematological diseases by clinical examination; – Other conditions that lead to motor dysfunction (e.g. lameness, osteoarthrosis, rheumatoid arthritis, gouty arthritis), which render the neurological function examination unlikely to be assessed; – Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg), or renal or hepatic insufficiency (hepatic insufficiency is defined as an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value that is 1.5 times the upper limit of normal, renal insufficiency is defined as a serum creatinine concentration value that is over the upper limit of normal); – Other conditions or mental disorders which according to the judgement of researchers that restrict evaluation of mental function or render outcomes or follow-up unlikely to be assessed; – Woman with pregnancy, lactation, or woman who wants to be pregnant in recent; – Patient who is allergic to the study drug or has severe allergic constitution; – Patient with yellow thick slimy tongue coating; – Patient who has been participated in other drug or device clinical trials in recent 3 months. Stable angina pectoris of coronary artery disease Inclusion Criteria:

  • Diagnosis of qi deficiency and blood stasis syndrome – Diagnosis of stable angina pectoris of coronary artery disease – Age ≥ 35 and ≤ 80 years – Canadian Cardiovascular Society (CCS) Classification of Angina Pectoris classⅠ-Ⅲ – Patient or legally authorized representative has signed informed consent. Exclusion Criteria:

  • Acute coronary syndrome or unstable angina pectoris in the prior 3 months, or other heart diseases (e.g. cardiomyopathy, pericardial disease); – Severe cardiopulmonary insufficiency (congestive heart failure NYHA class IV, severe abnormal pulmonary function), or severe arrhythmias (e.g. rapid atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia); – Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg), or renal or hepatic insufficiency (hepatic insufficiency is defined as an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value that is 1.5 times the upper limit of normal, renal insufficiency is defined as a serum creatinine concentration value that is over the upper limit of normal); – Other conditions or mental disorders which according to the judgement of researchers that restrict evaluation of mental function or render outcomes or follow-up unlikely to be assessed; – Woman with pregnancy, lactation, or woman who wants to be pregnant in recent; – Patient who is allergic to the study drug or has severe allergic constitution; – Patient with yellow thick slimy tongue coating; – Patient who has been participated in other drug or device clinical trials in recent 3 months. Diabetic peripheral neuropathy Inclusion Criteria:

  • Diagnosis of qi deficiency and blood stasis syndrome – Diagnosis of diabetic peripheral neuropathies – Age ≥ 35 and ≤ 80 years – Patient or legally authorized representative has signed informed consent. Exclusion Criteria:

  • HbA1c >10% in the screening period; – Acute critical disease of diabetes mellitus in the prior 3 months (e.g. hyperglycemia and hypertonic syndrome, diabetic lactic acidosis, diabetic ketoacidosis); – Severe heart disease, brain disease, or kidney disease; – Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg), or renal or hepatic insufficiency (hepatic insufficiency is defined as an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value that is 1.5 times the upper limit of normal, renal insufficiency is defined as a serum creatinine concentration value that is over the upper limit of normal); – Patient with spinal cord injury, cervical or lumbar vertebra disease (nerve root compression, spinal stenosis, cervical or lumbar vertebra degenerative disease), or sequelae of cerebrovascular disease, neuromuscular junction or muscular disease; – Neuropathies caused by other diseases (e.g. Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), VitB deficiency, hypothyroidism, alcoholism, severe arteriovenous vasculopathy such as venous embolism, lymphangitis); – Other conditions or mental disorders which according to the judgement of researchers that restrict evaluation of mental function or render outcomes or follow-up unlikely to be assessed; – Woman with pregnancy, lactation, or woman who wants to be pregnant in recent; – Patient who is allergic to the study drug or has severe allergic constitution; – Patient with yellow thick slimy tongue coating; – Patient with red tongue and scanty tongue coating; – Patient who has been participated in other drug or device clinical trials in recent 3 months.

Gender Eligibility: All

Minimum Age: 35 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Dongzhimen Hospital, Beijing
  • Collaborator
    • The Affiliated Hospital of Changchun University of Chinese Medicine
  • Provider of Information About this Clinical Study
    • Principal Investigator: Ying Gao, President of the Institute for Brain Disorders, Beijing University of Chinese Medicine – Dongzhimen Hospital, Beijing
  • Overall Official(s)
    • Ying Gao, MD, Principal Investigator, Dongzhimen Hospital
  • Overall Contact(s)
    • Ying Gao, MD, 0086-010-84013209, gaoying973@126.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.